Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247225824> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2247225824 endingPage "7645" @default.
- W2247225824 startingPage "7645" @default.
- W2247225824 abstract "7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly prolonged survival, delayed symptom progression, and improved quality of life versus placebo (Shepherd et al, N Engl J Med 2005;353:123–32). TRUST is an open label, non- randomized trial initiated to provide erlotinib access to pts with advanced NSCLC. Methods: Eligible pts had stage IIIb/IV NSCLC, and had failed or were unsuitable for chemotherapy. Erlotinib (150 mg/d p.o.) was given until disease progression or unacceptable toxicity. Pts were monitored monthly. Results: In November 2006, data were available for 5,015 pts (ITT population) from 51 countries. Median age was 63y (range 19–95). Pt characteristics (%) were: male/female 62/38; Caucasian/Oriental/other 76/19/5; non-smoker/ex- or current-smoker 28/71 (no data 1); ECOG PS 0/1/2/3 21/53/20/6; adenocarcinoma/squamous cell/other 53/25/21; stage IIIb/IV 22/78; erlotinib 1st/2nd/3rd-line/other 14/48/37/1. Safety data were available for 4,423 pts, 55% of whom had at least one adverse event (AE). Only 5% had one or more erlotinib- related serious AEs, the most common being gastrointestinal (GI) disorders (86 pts; 63 grade [gr] 3/4). 6% of pts discontinued treatment due to erlotinib-related AEs: GI disorders in 96 pts (54 gr 3/4), skin disorders in 92 (50 gr 3/4). Unexpected erlotinib-related AEs occurred in 10% of pts (4% gr 1, 3% gr 2, 3% gr 3/4). As expected, rash was observed in 70% of pts, with the majority (84%) being of gr 1/2. 80% pts received >4 weeks of erlotinib. Among 4,405 pts, only 14% had dose reductions, mainly due to rash (83%) and diarrhea (21%). Similar safety results were seen for 2nd-line pts only. Efficacy for all and 2nd-line pts will be presented. Conclusions: These results, achieved through routine clinical use of erlotinib in unselected pts with advanced NSCLC, confirm the favorable tolerability profile seen with erlotinib in selected patients in the clinical trial setting. [Table: see text]" @default.
- W2247225824 created "2016-06-24" @default.
- W2247225824 creator A5003892829 @default.
- W2247225824 creator A5008857351 @default.
- W2247225824 creator A5020822985 @default.
- W2247225824 creator A5032386417 @default.
- W2247225824 creator A5035063101 @default.
- W2247225824 creator A5039952118 @default.
- W2247225824 creator A5040142639 @default.
- W2247225824 creator A5062933842 @default.
- W2247225824 creator A5072563857 @default.
- W2247225824 creator A5073572288 @default.
- W2247225824 date "2007-06-20" @default.
- W2247225824 modified "2023-10-14" @default.
- W2247225824 title "Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study" @default.
- W2247225824 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.7645" @default.
- W2247225824 hasPublicationYear "2007" @default.
- W2247225824 type Work @default.
- W2247225824 sameAs 2247225824 @default.
- W2247225824 citedByCount "8" @default.
- W2247225824 countsByYear W22472258242012 @default.
- W2247225824 crossrefType "journal-article" @default.
- W2247225824 hasAuthorship W2247225824A5003892829 @default.
- W2247225824 hasAuthorship W2247225824A5008857351 @default.
- W2247225824 hasAuthorship W2247225824A5020822985 @default.
- W2247225824 hasAuthorship W2247225824A5032386417 @default.
- W2247225824 hasAuthorship W2247225824A5035063101 @default.
- W2247225824 hasAuthorship W2247225824A5039952118 @default.
- W2247225824 hasAuthorship W2247225824A5040142639 @default.
- W2247225824 hasAuthorship W2247225824A5062933842 @default.
- W2247225824 hasAuthorship W2247225824A5072563857 @default.
- W2247225824 hasAuthorship W2247225824A5073572288 @default.
- W2247225824 hasConcept C121608353 @default.
- W2247225824 hasConcept C126322002 @default.
- W2247225824 hasConcept C141071460 @default.
- W2247225824 hasConcept C143998085 @default.
- W2247225824 hasConcept C197934379 @default.
- W2247225824 hasConcept C2776256026 @default.
- W2247225824 hasConcept C2778087573 @default.
- W2247225824 hasConcept C2779438470 @default.
- W2247225824 hasConcept C2908647359 @default.
- W2247225824 hasConcept C71924100 @default.
- W2247225824 hasConcept C90924648 @default.
- W2247225824 hasConcept C99454951 @default.
- W2247225824 hasConceptScore W2247225824C121608353 @default.
- W2247225824 hasConceptScore W2247225824C126322002 @default.
- W2247225824 hasConceptScore W2247225824C141071460 @default.
- W2247225824 hasConceptScore W2247225824C143998085 @default.
- W2247225824 hasConceptScore W2247225824C197934379 @default.
- W2247225824 hasConceptScore W2247225824C2776256026 @default.
- W2247225824 hasConceptScore W2247225824C2778087573 @default.
- W2247225824 hasConceptScore W2247225824C2779438470 @default.
- W2247225824 hasConceptScore W2247225824C2908647359 @default.
- W2247225824 hasConceptScore W2247225824C71924100 @default.
- W2247225824 hasConceptScore W2247225824C90924648 @default.
- W2247225824 hasConceptScore W2247225824C99454951 @default.
- W2247225824 hasIssue "18_suppl" @default.
- W2247225824 hasLocation W22472258241 @default.
- W2247225824 hasOpenAccess W2247225824 @default.
- W2247225824 hasPrimaryLocation W22472258241 @default.
- W2247225824 hasRelatedWork W2015910003 @default.
- W2247225824 hasRelatedWork W2017389411 @default.
- W2247225824 hasRelatedWork W2022229528 @default.
- W2247225824 hasRelatedWork W2037082948 @default.
- W2247225824 hasRelatedWork W2056320953 @default.
- W2247225824 hasRelatedWork W2069129404 @default.
- W2247225824 hasRelatedWork W2069371231 @default.
- W2247225824 hasRelatedWork W2134035700 @default.
- W2247225824 hasRelatedWork W2186047679 @default.
- W2247225824 hasRelatedWork W2383050851 @default.
- W2247225824 hasVolume "25" @default.
- W2247225824 isParatext "false" @default.
- W2247225824 isRetracted "false" @default.
- W2247225824 magId "2247225824" @default.
- W2247225824 workType "article" @default.